Family Vaccine Protection Act

Bill Number

H.R. 3701

Origin Chamber

House

Congress

119th Congress, Session 1

Policy Area

Health

Status

Introduced

Latest Action

2025-06-04: Referred to the House Committee on Energy and Commerce.

Last Updated

2026-07-01T08:08:02Z

AI-Generated Summary

Purpose of the Legislation

The Family Vaccine Protection Act (H.R. 3701) aims to formally establish in law the Advisory Committee on Immunization Practices (ACIP), a group that advises on vaccine use. It ensures recommendations are based on strong scientific evidence to promote safe and effective vaccination in the U.S. civilian population. The bill also updates rules for compensating vaccine-related injuries to require evidence-based changes.

Key Provisions

• Establishment and Duties of ACIP:
• Codifies ACIP as a federal advisory committee under the Public Health Service Act, requiring it to provide advice, guidance, and recommendations to the CDC Director on using licensed vaccines to prevent diseases.
• Recommendations must rely on the "preponderance of the best available, peer-reviewed scientific evidence" (meaning most reliable studies support the decision).
• ACIP must review new vaccines or new uses for existing vaccines within 90 days of approval, prioritize breakthrough therapies (fast-tracked treatments) and emergency vaccines, and update Congress on progress.
• ACIP maintains lists of recommended vaccines for health insurance coverage (under the Affordable Care Act) and the Vaccines for Children Program (free vaccines for eligible kids).

• Adoption and Oversight of Recommendations:
• The CDC Director must adopt ACIP recommendations unless they lack scientific support, in which case the Director publishes reasons and notifies congressional committees within 48 hours.
• If the HHS Secretary or CDC Director acts against an ACIP recommendation (e.g., on insurance or program coverage), they must explain the scientific basis and notify Congress within 48 hours.
• ACIP can revise or withdraw recommendations if new evidence emerges.

• Administration and Operations:
• ACIP reports to the CDC Director, who informs HHS leadership and Medicare/Medicaid officials.
• Meetings occur at least three times a year, plus within 90 days of new vaccine approvals; most are open to the public.
• Membership: 15-19 expert members (appointed by HHS Secretary from Comptroller General recommendations) serving 4-year terms (Chair: 7 years), plus 6 non-voting ex-officio members from agencies like FDA and NIH. Includes expertise in immunology, epidemiology, and public health.
• Allows subcommittees for specialized work and non-voting liaisons from groups like the American Medical Association.
• Support from CDC's National Center for Immunization and Respiratory Diseases; authorizes $2.8 million annually (2026-2029) for operations.

• Vaccine Injury Compensation Update:
• Amends the National Vaccine Injury Compensation Program to require changes to the Vaccine Injury Table (list of compensable injuries) to be backed by scientific evidence on vaccine safety or effectiveness.

• Rule of Construction:
• Preserves ACIP's existing authorities unless explicitly changed.

Significant Changes to Existing Law

• Codification of ACIP: Previously operating under federal advisory rules without specific statutory backing, ACIP is now embedded in the Public Health Service Act, giving it permanent legal status and detailed operational rules (e.g., evidence standards, timelines, congressional notifications).
• Evidence Requirements: Introduces mandatory use of peer-reviewed science for recommendations, adoptions, rejections, and Vaccine Injury Table changes, which were not as explicitly required before.
• Accountability Measures: Adds transparency like public publication of decisions and rapid congressional alerts for deviations, plus quorum flexibility (allowing ex-officio members to vote temporarily if needed).
• No Limits on Prior Duties: Maintains ACIP's role in insurance and child vaccine programs without alteration.

Potential Impacts

• Government Agencies: Increases workload and transparency for HHS, CDC, and FDA in reviewing and responding to ACIP; ensures faster vaccine evaluations during emergencies (e.g., pandemics). Authorizes dedicated funding to support operations.
• Citizens: Promotes evidence-based vaccine recommendations, potentially improving access to covered vaccines via insurance and free programs for low-income children. Enhances public trust through open processes but could delay coverage if recommendations are rejected.
• International Relations: Minimal direct impact, though it lists the Canadian National Advisory Committee on Immunization as a potential liaison, fostering minor cross-border collaboration on vaccine standards.

Main Stakeholders Affected

• Government Entities: HHS, CDC (provides support and implements recommendations), FDA (vaccine licensing), CMS (insurance and child vaccine programs), and congressional committees (Energy and Commerce; Health, Education, Labor, and Pensions) for oversight.
• Health Professionals and Organizations: Doctors, nurses, epidemiologists, and groups like the American Academy of Pediatrics or Infectious Diseases Society of America, who serve as members or liaisons.
• Vaccine Manufacturers and Industry: Companies (e.g., via Biotechnology Innovation Organization) benefit from structured reviews of new products but face stricter evidence hurdles for approvals or injury table changes.
• Citizens and Public: Parents, children in the Vaccines for Children Program, and general population relying on vaccinations; vaccine injury claimants gain evidence-based protections in compensation processes.
• Public Health Advocates: Organizations focused on immunization (e.g., Association of Immunization Managers) influence via input.

Notable Legal, Constitutional, or Political Implications

• Legal: Strengthens ACIP's independence and evidence-based mandate, potentially reducing challenges to recommendations in court by emphasizing science over discretion. Enhances accountability through mandatory notifications, which could lead to more congressional scrutiny of HHS decisions.
• Constitutional: No direct implications; aligns with Congress's authority over public health under the Commerce Clause and spending powers (e.g., funding vaccine programs).
• Political: Promotes depoliticization of vaccine policy by tying actions to scientific evidence, which may limit executive overrides but invite debates on what constitutes "best available" evidence during controversies like public health emergencies. The bill's focus on family protection could appeal across parties but highlight tensions between rapid response needs and procedural rigor.

This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.

Sponsor

Rep. Pallone, Frank [D-NJ-6]

Cosponsors (78)

Rep. Schrier, Kim [D-WA-8], Rep. Matsui, Doris O. [D-CA-7], Rep. Castor, Kathy [D-FL-14], Rep. Dingell, Debbie [D-MI-6], Rep. Johnson, Henry C. "Hank" [D-GA-4], Rep. Nadler, Jerrold [D-NY-12], Del. Norton, Eleanor Holmes [D-DC-At Large], Rep. Jayapal, Pramila [D-WA-7], Rep. Trahan, Lori [D-MA-3], Rep. Auchincloss, Jake [D-MA-4], Rep. Veasey, Marc A. [D-TX-33], Rep. Landsman, Greg [D-OH-1], Rep. McClellan, Jennifer L. [D-VA-4], Rep. Krishnamoorthi, Raja [D-IL-8], Rep. Beatty, Joyce [D-OH-3], Rep. Fletcher, Lizzie [D-TX-7], Rep. Bonamici, Suzanne [D-OR-1], Rep. Hayes, Jahana [D-CT-5], Rep. Carter, Troy A. [D-LA-2], Rep. DeGette, Diana [D-CO-1], Rep. Barragán, Nanette Diaz [D-CA-44], Rep. Casten, Sean [D-IL-6], Rep. DelBene, Suzan K. [D-WA-1], Rep. Morrison, Kelly [D-MN-3], Rep. Quigley, Mike [D-IL-5], Rep. Doggett, Lloyd [D-TX-37], Rep. Ruiz, Raul [D-CA-25], Rep. Mullin, Kevin [D-CA-15], Rep. Tonko, Paul [D-NY-20], Rep. Menendez, Robert [D-NJ-8], Rep. Amo, Gabe [D-RI-1], Rep. Craig, Angie [D-MN-2], Rep. Soto, Darren [D-FL-9], Rep. Deluzio, Christopher R. [D-PA-17], Rep. Underwood, Lauren [D-IL-14], Rep. Dean, Madeleine [D-PA-4], Rep. Budzinski, Nikki [D-IL-13], Rep. Cohen, Steve [D-TN-9], Rep. Kelly, Robin L. [D-IL-2], Rep. Whitesides, George [D-CA-27], Rep. Elfreth, Sarah [D-MD-3], Rep. Larson, John B. [D-CT-1], Rep. Scanlon, Mary Gay [D-PA-5], Rep. Wasserman Schultz, Debbie [D-FL-25], Rep. Magaziner, Seth [D-RI-2], Rep. Thompson, Mike [D-CA-4], Rep. Sewell, Terri A. [D-AL-7], Rep. Clarke, Yvette D. [D-NY-9], Rep. Moulton, Seth [D-MA-6], Rep. Davis, Danny K. [D-IL-7] and 28 more

Recent Actions

• 2025-06-04: Referred to the House Committee on Energy and Commerce.
• 2025-06-04: Introduced in House
• 2025-06-04: Introduced in House

Bill Versions

• Family Vaccine Protection Act — issued 2025-06-04 — PDF (22 pages)

Related Bills

• S. 3323 (119th Congress)